breast cancer

News

Pfizer's new drug data in breast cancer draws muted response

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

Woman attended by female radiologist having a mammogram

NHS trial puts AI for breast cancer screening under scrutiny

Nearly 700,000 women will be recruited into an NHS trial of AI tools for breast cancer screening, in the hope of relieving pressure on radiologists.

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

Enhertu gets first okay for HER2-ultralow breast cancer

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

News

AZ, Daiichi get FDA nod for Dato-DXd in breast cancer

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.

Pfizer's new drug data in breast cancer draws muted response

Data cues up AZ oral SERD filing in first-line breast cancer

NHS trial puts AI for breast cancer screening under scrutiny

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Enhertu gets first okay for HER2-ultralow breast cancer

AZ, Daiichi get FDA nod for Dato-DXd in breast cancer

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

breast cancer

Editor's Picks